-

Agilent and UC San Diego Launch Center of Excellence in Cellular Intelligence

Agilent CoE supports research on how cells function and adapt, revealing new insights into biological processes

SANTA CLARA, Calif. & SAN DIEGO--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, and the University of California San Diego (UC San Diego), one of the top-ranked public research universities in the world, today announced an innovative scientific collaboration to establish the Agilent Center of Excellence (CoE) in Cellular Intelligence.

The Agilent CoE, located at UC San Diego’s School of Medicine, will foster collaboration and innovation among researchers from Agilent and UC San Diego, and other institutions and industry partners. The CoE will serve as a hub for academic and pharma/biopharma researchers in the region, enabling access to vital analytical instrumentation and providing education, training, and application development opportunities.

"This important initiative will improve our understanding of disease mechanisms at the cellular level—and drive the development of better methods for editing and engineering cells to treat diseases, enhance immunity, and create novel bioproducts,” said Mike McMullen, Agilent President and CEO.

The CoE will leverage Agilent instrumentation, including cell analysis and mass spectroscopy solutions, to support an ambitious transdisciplinary initiative: Decode Eukaryotic Cellular Intelligence, a research program that aims to understand how eukaryotic cells sense, decide, and act in complex and uncertain environments, with implications for health and disease.

“We are thrilled to partner with Agilent to launch the Agilent CoE in Cellular Intelligence at UC San Diego, which will advance our understanding of the fundamental principles of life and the origin of biological complexity,” added Dr. Pradipta Ghosh, Professor of Medicine and Cellular and Molecular Medicine at UC San Diego and Founding Director of the program.

The program is based on the hypothesis that eukaryotic cells function as deep reinforcement learning (RL) agents that use interlinked switch circuits of biological intelligence to adapt and survive. It combines experimental, computational, and theoretical approaches to decode the molecular and cellular mechanisms of these switch circuits and explore their implications for health and disease.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

About UC San Diego

At the University of California San Diego, a culture of risk-taking, collaboration and innovation emerged early on. Established in 1960, UC San Diego has been shaped by exceptional scholars who aren’t afraid to push boundaries, challenge expectations and redefine conventional wisdom in order to make our world better. The only criterion our founders had for their campus was that it must be distinctive – and being experimental has been the norm since day one. UC San Diego is a top-ranked public research institution and one of the most applied to universities in the nation. Learn more at www.ucsd.edu.

Contacts

Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

Kellie Woodhouse
UC San Diego
+1.858.226.5609
kwoodhouse@ucsd.edu

AGILENT TECHNOLOGIES INC

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

Kellie Woodhouse
UC San Diego
+1.858.226.5609
kwoodhouse@ucsd.edu

More News From AGILENT TECHNOLOGIES INC

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced...

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call also will be available on the website...

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a...
Back to Newsroom